Early stage investors, fundraising CEOs, scientist entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection
Welcome to RESI - - - - - - - - - - - - - - - - - - - 2

RESI Agenda - - - - - - - - - - - - - - - - - - - - - - 3

RESI Innovation Challenge - - - - - - - - - - -  6

Sponsors, Exhibitors & Media Partners - - - - - - - - - - - - - - - - - - - - 12

Track 1: Global Investor Panels - - - - - - - - - - - - - - - - - - - - - - - - - - 18

Track 2: Entrepreneur Workshops & MWE 2019 Symposium - - - - - - 26

Track 3: Entrepreneur Pitch Sessions - - - - - - - - - - - - - - - - - - - - -  33

Track 4: Partnering Forum - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 39
Life Science Nation (LSN) would like to welcome you to our inaugural RESI Asia Week. With the support of our title sponsors NARLabs, McDermott Will & Emery, and Stetson Family Office, we have brought RESI to Taipei. We are delighted to be here, and would like to thank all our sponsors for giving us the opportunity to bring the Pacific Rim into RESI’s life science networking ecosystem. We would also like to thank our Gold Sponsors, BE Capital, National Taiwan University, Taipei Medical University, Taiwania Capital and PwC Taiwan.

For years, LSN has helped early stage companies in the biotech, medtech, diagnostic and digital health realms connect with investors. RESI Partnering is our most powerful tool with which to build these connections. RESI Partnering’s online platform allows you to send messages to other attendees prior to the event, read the profiles of other attendees, and book 30 minute face to face meetings. RESI’s unique investor profiles allow startups to focus on meeting with investors that are a fit for their sector, products, and stage of development. We have held RESI life science partnering events across North America since 2013 and we are excited to bring this model to Asia, because we believe that meeting one on one is key to making the connections that will move new technologies toward commercialization. Every RESI event has created hundreds of entrepreneur-investor meetings, which in turn have led to countless investments and deals.

As we took RESI international, we came to learn a lot about how the life science innovation landscape in Asia works and what makes investors in the region tick. In response, we have added a new element to RESI: an all-day Entrepreneur Pitch Sessions track, in which the our RESI Innovation Challenge participants will give short presentations of their technologies all day, and will receive feedback from panels of investors and experts. This is the first time RESI has featured an all-day pitch track, and we’re excited to hear from all the innovative participants throughout the day.

Additionally, in RESI’s exhibit hall you can view poster presentations from the RESI Innovators. You can vote throughout the day on the Innovation Challenge competitors: Inside your RESI badge you’ll find five tokens of RESI Cash you can use to “invest” in the most promising of these technologies. The winning companies that attract the greatest amount of “investment” will be announced at the cocktail reception tonight.

We are delighted to present RESI’s investor panels and entrepreneur workshops, including expert legal content from McDermott Will & Emery. RESI attendees have the opportunity to hear investor panels and workshops focused on the early stage investment landscape, such as International Collaboration from our sponsors PWC Taiwan, and investor panels on the capital landscape for key local technologies such as Smart Hospital & Homecare, Early Stage Therapeutic Investors and Medical Device & Diagnostic Investors. Together with our sponsors Stetson Family Office, LSN will present a Fireside Chat with Global Family Office BioForum. We would like to thank all our speakers and presenters for taking part in RESI Taipei.

We hope you make some great connections today. We look forward to seeing you again in 2020 - you can join us on January 14th for our annual San Francisco event.

Sincerely,

Dennis Ford
Founder & CEO, Life Science Nation
Creator of RESI Conference Series
<table>
<thead>
<tr>
<th>Time</th>
<th>Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 - 8:00 AM</td>
<td>Registration</td>
</tr>
<tr>
<td>8 - 8:50 AM</td>
<td>PANEL, WORKSHOP &amp; PITCH SESSIONS START AT 9 AM</td>
</tr>
<tr>
<td>8:00 - 9:00 AM</td>
<td>EARLY STAGE THERAPEUTICS INVESTORS</td>
</tr>
<tr>
<td></td>
<td>Bringing the Newest Therapies to the Clinic</td>
</tr>
<tr>
<td>9:00 - 10:00 AM</td>
<td>LIFE SCIENCE NATION FUNDRAISING BOOTCAMP</td>
</tr>
<tr>
<td>10:00 - 11:00 AM</td>
<td>PITCH SESSION 1 MEDICAL DEVICE</td>
</tr>
<tr>
<td></td>
<td>MORNING</td>
</tr>
<tr>
<td></td>
<td>EARLY STAGE PARTNERING FORUM</td>
</tr>
<tr>
<td>10:00 - 10:50 AM</td>
<td>STETSON FAMILY OFFICE FIRESIDE CHAT WITH GLOBAL FAMILY OFFICE BIOFORUM</td>
</tr>
<tr>
<td></td>
<td>PITCH SESSION 2 MIX OF THERAPEUTICS DIAGNOSTICS DIGITAL HEALTH</td>
</tr>
<tr>
<td>11:00 - 11:50 AM</td>
<td>DIGITAL HEALTH &amp; AI IN HEALTHCARE</td>
</tr>
<tr>
<td></td>
<td>Cutting Edge Computing Creates New Opportunities for Healthcare Investors</td>
</tr>
<tr>
<td></td>
<td>PITCH SESSION 3 THERAPEUTICS</td>
</tr>
<tr>
<td>12:00 - 1:00 PM</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>1:00 - 1:50 PM</td>
<td>SMART HOSPITAL &amp; HOME CARE</td>
</tr>
<tr>
<td></td>
<td>Defining the Future of Care Delivery</td>
</tr>
<tr>
<td>2:00 - 2:50 PM</td>
<td>TALES FROM THE ROAD</td>
</tr>
<tr>
<td></td>
<td>Outside Taiwan Entrepreneurs Talking about Successful Partnerships with Taiwan</td>
</tr>
<tr>
<td>3:00 - 3:50 PM</td>
<td>MEDICAL DEVICE &amp; DIAGNOSTICS</td>
</tr>
<tr>
<td></td>
<td>Investing in Novel Engineering &amp; New Generation of Technologies</td>
</tr>
<tr>
<td></td>
<td>Changing Treatment Paradigms</td>
</tr>
<tr>
<td>4 - 4:50 PM</td>
<td>PANEL, WORKSHOP &amp; PITCH SESSIONS END AT 4 PM</td>
</tr>
<tr>
<td>4:30 - 7:00 PM</td>
<td>Cocktail Reception</td>
</tr>
</tbody>
</table>
Functioning as the main government think-tank for science and technology policy, STPI aims to support the government on S&T policy planning, evaluation and program management with advice regarding mid- and long-term technological development.
Better Health at Lower Cost Coalition
To Advance Sustainable Development Goal #3

“Ensure healthy lives and promote well-being for all at all ages”

- Alzheimer’s Disease today kills more people than breast cancer or prostate cancer combined.
- In the United States alone, the cost to government which excludes the substantial family care costs, is $279 billion currently and is estimated to grow to $1.1 trillion by 2050.

“At least 30% of Alzheimer’s disease is related to factors that can be influenced, including blood pressure, depression, education and physical activity. With no Alzheimer’s disease drug trial yet proving successful we need to turn to these preventable measures which have proven beneficial even in people with genetic susceptibility for dementia.” Miia Kivipelto, PhD, Lead Researcher, the FINGER study and the World Wide FINGERS Initiative, in 25 countries.

This study is considered to be the baseline for demonstrating that lifestyle intervention of nutritional guidance, exercise, cognitive training and management of vascular risk could greatly prevent or postpone cognitive decline. Dr. Kivipelto serves as a Scientific Advisor to the Stetson Family Office.

Inviting Others to Join
Stetson Family Office and the Global Partnerships Forum are forming a partnership of Businesses, Governments, Foundations and Family Office for creating a “Go To” platform for prevention of chronic diseases with a focus on Alzheimer’s, advocacy of healthy living choices, and training of our Global Health Community. Join us.

Stetson Family Office
Global Family Office BioForum

www.globalfamilyofficebioforum.com
www.globalbetterhealth.org
chuck@stetsonfamilyoffice.com

GLOBAL PARTNERSHIPS FORUM
Amir Dossal
President, Global Partnerships Forum
dossal@partnerships.org
www.partnerships.org
The RESI Innovation Challenge is a virtual investment contest, and the investor is you!

As you explore the exhibit hall, you will encounter RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will find five RESI Cash tokens that you can use to ‘invest’ in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 23,000.

- First Prize: Complimentary tickets to 3 RESI Conference Series events of your choice (2 tickets per event)
- Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event)
- Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets)
<table>
<thead>
<tr>
<th>Easel</th>
<th>RESI Innovators</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BELKIN Laser Technology</td>
</tr>
<tr>
<td>2</td>
<td>CLEARFLOW - Clearing the Path to Recovery</td>
</tr>
<tr>
<td>3</td>
<td>GRI BIO</td>
</tr>
<tr>
<td>4</td>
<td>Jello</td>
</tr>
<tr>
<td>5</td>
<td>Allgenisis Biotherapeutics</td>
</tr>
<tr>
<td>6</td>
<td>KUPANDO</td>
</tr>
<tr>
<td>7</td>
<td>promaxo</td>
</tr>
<tr>
<td>8</td>
<td>世延生医股份有限公司 See&amp;Treatment LTD.</td>
</tr>
<tr>
<td>9</td>
<td>Huijia</td>
</tr>
<tr>
<td>10</td>
<td>BLUSENSE DIAGNOSTICS</td>
</tr>
<tr>
<td>11</td>
<td>Jubo health - Smart Ageing Tech</td>
</tr>
<tr>
<td>12</td>
<td>Reliance Biosciences</td>
</tr>
<tr>
<td>13</td>
<td>COASTAR Therapeutics</td>
</tr>
<tr>
<td>14</td>
<td>Conzian</td>
</tr>
<tr>
<td>15</td>
<td>RESEARCH BIOSCIENCES</td>
</tr>
<tr>
<td>16</td>
<td>N2 Technologies - Innovating for better care</td>
</tr>
<tr>
<td>17</td>
<td>Geoll</td>
</tr>
<tr>
<td>18</td>
<td>CHARSIRE BIOSCIENCES</td>
</tr>
<tr>
<td>19</td>
<td>TERRAN BIOSCIENCES</td>
</tr>
<tr>
<td>20</td>
<td>BEL Bio-Pharmaceutical Co. Ltd. - 貝爾克斯生技股份有限公司</td>
</tr>
<tr>
<td>21</td>
<td>BalinBac Therapeutics</td>
</tr>
<tr>
<td>22</td>
<td>NAVI Medical Technologies</td>
</tr>
<tr>
<td>23</td>
<td>VSENSE</td>
</tr>
<tr>
<td>24</td>
<td>AESOP - AI-Enhanced Safety of Prescription</td>
</tr>
<tr>
<td>25</td>
<td>ATP BioPharm</td>
</tr>
<tr>
<td>26</td>
<td>CytoArm</td>
</tr>
<tr>
<td>27</td>
<td>DermAI</td>
</tr>
<tr>
<td>28</td>
<td>AlphaGABA - For early detection of cancer</td>
</tr>
<tr>
<td>29</td>
<td>AHEAD</td>
</tr>
<tr>
<td>30</td>
<td>ONE TEST - Carmentix - VASCOR</td>
</tr>
</tbody>
</table>
BELKIN Laser is a clinical-stage medical device company, developing an intuitive, automated, one-second glaucoma laser treatment, aimed at revolutionizing accessibility to first-line glaucoma care. More than 20M glaucoma patients reside in China, 20% of the global glaucoma population, but there are less than 500 glaucoma specialists to treat them. High-end technology is crucial to bridge this gap. BELKIN’s automated, non-contact, painless treatment is activated by a touchscreen, controlled by a high-resolution image acquisition algorithm and a proprietary eye tracker. It can be easily used by all 36,000 ophthalmologists in China, dramatically increasing the number of treated patients, both in central and rural areas. Glaucoma is the leading cause of irreversible blindness in China. BELKIN’s technology is applicable for all glaucoma types, and is especially designed for Angle Closure Glaucoma, most common among Chinese populations.

The PleuraFlow® Active Clearance Technology® System offers a safe way to proactively maintain chest tube patency, minimizing complications from retained blood due to ineffective evacuation of blood and fluids after cardiothoracic surgery. Results from a recent prospective clinical trial showed a 42% decrease in reinterventions and a 30% decrease in postoperative AFib (POAF) with the PleuraFlow ACT. Other recent published studies link retained blood with longer Length of Stay (LOS), higher hospital readmissions, as well as increased infection rates, acute kidney injury, and mortality.

GRI Bio is a clinical stage company focused on treating fibrosis and autoimmunity including Fatty Liver (e.g. NASH and alcoholic hepatitis), IPF and MS. GRI’s technology platform has been proven in disease models, scientific journals and has been shown to improve liver function in human patients. Our GRI-0621 program (Phase 2) treats fibrotic disease by inhibiting NKT I cells which leads to suppression of multiple fibrotic pathways, including TGF-β1 HSC and M2 macrophages. Our GRI-0124 program (Phase 2) targets NKT II cells as a potential therapy for progressive MS. Our program has been shown to impact both adaptive and innate components of MS, including inhibition of microglial cells. GRI is seeking licensing partners and investors for our Phase 2 programs.

JelloX is a next generation pathology company that revolutionizes the way to imaging tumor samples. With JelloX 3D imaging technology that not only scans the clinical tissue sample as a whole but also preserves its structural integrity to the cellular level, we now have access to hundreds times more data from a single piece of tumor tissue. Along with our AI Algorithm and 3D pathology database, we are building an auxiliary diagnostic system for pathologists to make better clinical decisions in cancer diagnosis.

Allgenesis is a clinical stage biopharmaceutical company focused on the research and development of novel medicines in ophthalmology. Vision impairment is a growing problem worldwide that affects a patient’s quality of life and has been linked to increased injury, and worsening of existing disease. The ophthalmology market is expected to exceed $30B USD in the next 5 years with retinal diseases accounting for nearly 50% of the market. Current projects in the pipeline for Allgenesis include AG-73305, a potential blockbuster drug for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (wAMD), and other retinal diseases and AG-86893 for pterygium.

Kupando, newly founded company, develops two program. A small molecule TRL 4/7 immum stimulatory molecule in oncology and infectious diseases with a license form UCSD. TLR 7 is a validated target in oncology. This novel compound will allow for systemic administration. Synergies with check point inhibitors has been demonstrated in vivo. A MAAC1 down regulating small molecule as a preventive treatment for metastasis based on an invention of Ulrike Stein. Metastasis remain one of the major issues in oncology. The license is from Charite and MDC in Berlin. Both compounds are in preclinical stage.

Promaxo is a medical technology company that develops and commercializes office-based modular MRI and MRI based technologies. The Company is currently focused on advancing the solutions for prostate disease management and other urology and pelvic conditions.

In vitro diagnostics of early stage human oral cancer with Saliva from the high-risk populations.

G-SYN BIOMEDICAL TECHNOLOGY INC. dedicates in the resolution to diseases incurring from Cell Hypoxia, such as cancer, diabetes, hypertension, dementia and other chronic diseases. The Founder of G-Syn, Dieter Chang has been researching on the subject of Hypoxia and its medical theory for years, and had developed the structure of Anti-Hypoxia industry in the field of medical treatment, healthcare system (online & offline), self-health management instruction, new wearable device, exercise plan, and diet plan. G-SYN will continue to build up Anti-Hypoxia healthcare system and wish to bring people a healthy life with vitality in an efficient, effective and economical way.
Huijia Health has an extensive product line featuring their patented core technology, a Non-invasive Fiber Optic Physiological Monitoring Technology (nFOPT®), that does not use electromagnetic waves, and has a high sensitivity to detect vital signs (breathing, heart rate, sleep analysis etc.). Huijia’s products include smart pillows, smart mattresses, smart wheelchair cushions and a complete smart care system. nFOPT® technology and the smart care system has won multiple awards, including 2017 R&D 100 Awards, 2016 APICTA Awards, 2017 HQIC Awards-Smart Hospital Group and 2019 ECI GOLD & GRAND Awards. nFOPT® has been used by baby care centers for over 8 years and it’s trusted, including current use by 220 professional care centers caring for 100,000 infants.

BluSense Diagnostics ApS is a young SME based in Copenhagen, Denmark. Since its incorporation in 2014, the company has rapidly grown to a large team of qualified scientists and engineers around the globe. By combining state-of-the-art Scandinavian bio-engineering and medical device with first-rate Taiwanese hardware, software and manufacturing engineering, BluSense Diagnostics ApS has developed a breakthrough nanotechnology-based point-of-care blood testing platform for the diagnostics of infectious diseases. The goal of BluSense Diagnostics ApS is to provide better, more accurate, and easier-to-interpret diagnostics solutions for the correct management of infected patients, with the intention of both reducing the health impact of the diseases, and optimizing the costs and efficiency of the patients management and disease containment programs.

Guzip is a spin-out company from Taipei Medical University. We are dedicated to DNA methylation analysis using biomarkers for clinical application. Our main focused product, M Pap is an endometrial cancer reagent, which detects the presence of endometrial cancer in pap specimens and gives us a quantifiable data for the disease and hopes to contribute great cause in women’s healthcare. The products we developed are combined with traditional smear and genetic methylation analysis. With high accuracy and many other advantages, our product has an opportunity to become the mainstream test reagent product in the Gynecology market. Our vision is to be a leading provider dedicated to the women’s healthcare arena, providing accurate, affordable, and safe medical solutions for women.

Coastar Therapeutics is a San Diego based startup focusing on virus delivery platform. We have a novel virus coating platform that can coat human cell membrane on each individual virus to evade immune system recognition and clearance. The company is currently focusing on oncolytic virus coating for cancer immunotherapy, but is also interested in AAV for gene therapy in the future.

Conzian is a digital healthcare provider, with current solution focusing on the intelligent rehabilitation at home prior/after a knee surgery. The total solution, KNEESUP compact, contains a smart device tracking movement data, monitoring how patients do the rehab exercise and transmitting data to KNEESUP App and Conzian cloud. Patients complete their daily rehab exercise with their own customized rehab plans and KNEESUP in time detects if patients do each movement correctly and provides a proper guide. We connect patients and doctors and improve rehabilitation performances. KOL surgeries are motivated for the increased patients’ compliance and accurate data for study publication. The market is huge and growing rapidly, around 1 million procedures/year in US.

Smart Ageing Tech aims to provide the most advanced mobile and integrated solution to stakeholders in the healthcare industry. The first product, Jubo Facility Solution, has been deployed in 28 long term care facilities, serving more than 3,000 elderly after launched in late 2018. The company spins off from an experienced research team across nursing, social work and engineering, led by Dr. Jessy Kang, at National Taiwan University. Smart Ageing Tech aims to provide the most advanced mobile and integrated solution to stakeholders in the healthcare industry. The first product, Jubo Facility Solution, has been deployed in 28 long term care facilities, serving more than 3,000 elderly after launched in late 2018. The company spins off from an experienced research team across nursing, social work and engineering, led by Dr. Jessy Kang, at National Taiwan University. It received USD 2.5 million angel fund in 2018, and has won multiple national awards which include Inno-Award of Taiwan Healthcare, Taiwan Small Medium Enterprise (SME) Innovation Award, and Best Healthcare Software (金漾奬). Currently, Smart Ageing Tech is planning its expansion to Pan-Asia and North America market.

Reliance Biosciences delivers frontier molecular diagnostics for the management of cancer. Using a simple blood test, known as liquid biopsy, test results provide personalized, real-time insight contributing to the physician's decision in disease management. Our proprietary microfluidic technology enables ultra-high sensitivity protein detection on exosomes, or bio-nanoparticles secreted from disease-specific cells, e.g. tumor cells deep inside the body. Current focus is: (1). Management of metastatic HER2-positive breast cancer and (2). Prediction of PD-L1 immunotherapeutic response. Our medical team includes physicians from the National Taiwan University Hospital, Harvard Medical School and Massachusetts General Hospital.

NZ Technologies Inc. (NZTech) is a technology company specializing in the design and manufacture of advanced Human Machine Interaction (HMI) products with applications in minimally invasive surgeries. TIPSO is the company’s flagship family of products - it has enabled surgeons to interact with operating room equipment and radiology imaging by utilizing unique and practical touchless interfaces. The products have emerged through years of innovation and collaboration with clinical thought leaders specialized in the field of minimally invasive surgery. Commercially available and deployed in various world-leading clinical institutions, TIPSO has delivered outstanding safety and economic benefits for the healthcare system. Increasing procedural efficiency, reducing operative time, and maintaining the surgeon’s cognitive focus are among the proven value propositions for the TIPSO product line.
AESOP Technology was founded in 2019 by a team of biomedical informaticians, physicians and pharmacists. We aim to create a smarter prescription error detection system through machine learning technology to enhance patient safety. Our non-intrusive overlay solution—MedGuard—sits on top of hospital systems which makes deployment in hospital faster and more cost-effective. MedGuard Features: (1) Medication Suggestions – Specialty specific and general medication suggestions for inappropriate prescriptions utilized. (2) Dual AI Engines – Boosted by probabilistic engine for unsupervised learning and reinforcement learning engine for continuous self-improvement. (3) Clinically Proven – Precisely alert inappropriate prescriptions and has been clinically proven to improve accuracy of medical coding. (4) Massive Medical Dataset – With 2.5 billion diagnosis codes and 4 billion medications, MedGuard is embedded with real and high-quality prescriptions.
ATP BioPharm is an energized start-up biotech company that will soon spin off from Taipei Medical University with a focus on drug development for unmet medical needs. We are developing compound MPT0G211, a first-in-class and oral selective small-molecule HDAC6 inhibitor, to against Multiple Myeloma and Alzheimer’s disease. The majority of the IND enabling studies for MPT0G211 has been completed and we will submit IND application to the US FDA in Q4 2020. Now, ATP BioPharm is seeking seed funding, co-development or licensing opportunities to accelerate the development process and proceed to clinical trials.

The CytoArm developed a novel bispecific-antibody (BsAb)-based culture platform technology for tumor-specific T cells. By using anti-tumor/anti-CD3 BsAbs of special structure to culture human PBMC, tumor-specific BsAb-armed T cells can be generated and expanded with purity over 90% in 10 days under the one-step method. It is a fast-culturing and low-cost platform to generate high pure tumor-specific T cells without viral gene transfection. In vivo experiments demonstrated highly efficient targeting and cytotoxicity of BsAb-armed T cells to human tumor cells without severe cellular cytokine release and significant toxicity. We had filed a Patent Cooperation Treaty (PCT) application to protect BsAb-armed T technology in 2018, and we are engaging in finding investments, building a patent portfolio and commercialization.

According to WHO, Melanoma of the skin is the 19th most commonly occurring cancer. There were nearly 300,000 new cases in 2018 and some of them can be fatal. But if people receive early treatment, the 5-year survival rate will be 99%. Therefore, we’ve developed a risk classifier, MoleMe, which makes user realize whether they should see a doctor based on novel DCNN framework and thousands of dermatologist-annotated data. With 94% AUROC, MoleMe has already accomplished more than 50,000 times of evaluation and raised the awareness of self-care management.

The Alpha6GABA team identified several α6 subunit-containing GABAA receptor-selective positive allosteric modulators (α6GABAAR-PAMs) effective in animal models of migraine, schizophrenia and Tourette syndrome, etc. The benzodiazepines sleep pills and allopregnanolone, a promising neurosteroid newly identified for postpartum depression, are also GABAAR PAMs while lacking subtype-selectivity. The candidate compound has promising safety pharmacology, pharmacokinetics and toxicity. It will be the first-in-class anti-psychocthic for both positive and negative symptoms, and anti-migraine (preventive and abortive) agent. Prof. Lih-Chu Chiou (National Taiwan University, Taiwan) initiated this project. Her first-in-class anti-psychotic for both positive and negative symptoms, and anti-migraine (preventive and abortive) agent. Her project team performed preclinical animal studies with the compounds synthesized by James Cook’s team (University of Wisconsin Milwaukee, USA) and having α6GABAAR-selectivity verified by Margot Ernst & Werner Sieghart’s team (Medical University of Vienna, Austria).

AHEAD focuses on the development and application of AI enabled diagnostic and disease assessment tools to blood cancer treatment. We have developed leukemia cell detection models which allow physicians to identify abnormal cases promptly and avoid delays in clinical decisions such as whether to proceed with a bone marrow transplant or not. Our vision is to enable AI to make decisions in the blood cancer treatment for every physician and to identify, with greater ease, optimization paths to better treatment strategies.

20/20 GeneSystems is now selling in the US and worldwide (including Beijing and Taipei) OneTest™: A new AI powered Multi-Cancer Blood Test & Machine Learning Algorithm for Broad Spectrum Early Cancer Detection (www.OneTest.AI). We are seeing revenue growth in the U.S. with licenses and distribution agreements entered in 2019 in China, Japan, the Middle East, and Europe. This product is believed to be the world’s first cancer screening blood test powered by a machine learning algorithm built from data from tens of thousands of individuals screened yearly in a real-world clinical setting. (Tests built with data from individuals tested before developing symptoms of cancer tend to be more reliable.) Ping An, one of the largest health insurance and digital health companies in China, is already a large investor in 20/20 and is helping to contribute to the success of our China strategy. Our Series C Round ($7-10 million) will be lead by a respected Silicon Valley VC with a proven track record of successful exits in diagnostics.

Carmentix a healthcare start-up that aims to reduce the incidence of preterm birth, one of the biggest unmet needs in pregnancy. Carmentix has discovered a novel panel of protein biomarkers with high sensitivity and specificity. It has validated these biomarkers clinically demonstrating outstanding accuracy which will enable clinicians to intervene at early stage of pregnancy and significantly reduce preterm birth rates.

Vascor has developed an innovative ventricular assist device (VAD) that treats advanced heart failure more safely and overcomes existing device shortcomings. Current VAD devices on the market, while extending life, have severe complications, including infection, bleeding, device malfunction, stroke and death. At least one of these complications occurs in 72% of IV AD patients during their first year of VAD use. Vascor’s patented failsafe non-rotary implantable counter pulsation heart assist device is powered by a transcathetar energy transmission system and addresses the root causes of these serious adverse events. The global VAD market is expected to grow from $1 Billion to $2 Billion in 2024. Our team includes a successful serial inventor with a winning track record and a seasoned CEO.
SPONSORS & EXHIBITORS

Title Sponsors

LIFE SCIENCE NATION
Connecting Products, Services & Capital

NAR Labs
National Applied Research Laboratories

McDermott Will & Emery

STETSON FAMILY OFFICE

Gold Sponsors

比翼資本
BE CAPITAL

比翼加速器
BE ACCELERATOR

pwc

資誠

TAIWANIA

NTU IL/O
INDUSTRY LIASON OFFICE
NATIONAL TAIWAN UNIVERSITY

BIO
Boston Innovation Capital

TAIPEI MEDICAL UNIVERSITY

Bronze Sponsors

財團法人生物技術開發中心
Development Center for Biotechnology

MEDMARC.
Treated Fairly

BioTaiwan
Taiwan Bio Industry Organization

Exhibitors

Global Bio & Investment
環球生技

The Chinese University of Hong Kong

ACADEMIA SINICA
National Biotechnology Research Park

VENTURE VALUATION
GLOBAL VALUATION SERVICES
Life Science Nation (LSN) is a global partnering ecosystem that allows early-stage companies with compelling technology assets to get plugged into the early-stage investor and channel partner’s radars with minimal cost and a big ROI. LSN is a global matching platform for early-stage buyers and sellers across the domains of Drugs, Devices, Diagnostics and Digital Health – the “4 Ds”. LSN curates two databases: a buy-side of global cross-border early-stage investors/partners and a sell-side of global cross-domain technology assets. LSN also offers a sourcing and ranking service for clients who need to source and rank technology assets for channel, pipeline and portfolio development. LSN owns and operates the Redefining Early Stage Investments (RESI) conference series, a funding superstructure that runs five times a year during J.P. Morgan in San Francisco (January), alongside BIO Europe (March), alongside BIO U.S (June), Boston (September) and Asia in Shanghai and Taipei (November). LSN also owns and operates the Focus on Cures Accelerator (FOC) that provides international startups a Boston-based footprint and helps them develop and execute a global investor and channel partner strategy. Learn more at www.lifesciencenation.com

Functioning as the main government think-tank for science and technology policy, Science and Technology Policy Research and Information Center (STPI) of the National Applied Research Laboratories aims to support the government on Science & Technology policy planning, evaluation and program management with advice regarding mid- and long-term technological development. Biomedical Ecosystem development office in Taiwan (BEST) of STPI aims to build a biomedical ecosystem which connects domestic innovation sources and strengthens international cooperation. According to the World Economic Forum (WEF) 2018, Taiwan ranks 4th on “Innovation Capability”. The mission of BEST Office is to assist Taiwan to remain highly competitive in Science and Technology fields.

McDermott Will & Emery is a global, industry-leading law firm offering mission-first business solutions that are equally informed by market intelligence and proven experience. With our strategic alliance with MWE China Law Offices in Shanghai and an office in Seoul, our team on the ground in the Asia/Pacific region is composed of top lawyers with demonstrated strength across intellectual property, transactional, litigation and regulatory law. That teams partners with our more than twenty offices in the US and Europe to support cross-border market entry, expansion and investment. At McDermott, we harness the power of collaboration to bring the right combination of people, skills and knowledge to bear at the right time. For decades, we have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of our team. This makes us uniquely qualified to help you move business initiatives across the finish line when it matters and anticipate what’s next.

MWE China Law Offices offers clients the full range of support and services they require as they progress through the various stages of the health care and life sciences continuum. We have counselled some of the world’s largest pharmaceutical and medical device companies, academic medical research centers, universities, investment banks, venture capital firms, and start-ups on matters critical to their continued growth and success. Our team, whether working alone or as a globally integrated team with our counterparts at McDermott Will & Emery, regularly serve a broad range of clients in the areas of: corporate & transactional, regulatory compliance, product liability, anti-trust and competition, anti-corruption and FCPA; tax; labor; international trade and dispute resolution issues.

The Stetson Family Office, established in 1919, has focused, among other things, on rebuilding the private equity healthcare eco-system globally and is working with a number of cities and states around the globe in addressing the Valley of Death for life science companies – year 0 when a company is formed to year 3 or later when typically institutional for-profit capital becomes available. www.stetsonfamilyoffice.com The Stetson Family Office and the Global Partnerships Forum are forming a partnership of businesses, governments, foundations and Family Offices to create a platform for: prevention of chronic diseases with a focus on Alzheimer’s, advocacy of healthy living choices and training of global healthy community. www.globalbetterhealth.org

BE Capital is a healthcare focused investment firm formed making investments into promising private and public hospital and healthcare technology ventures in the Greater China and U.S.

BE Accelerator, backed by BE Capital and Daren Medical Group, headquartered in Taiwan, offers a wide array of startup training programs to members of professional communities and to the broader public interested in innovation in Health-Tech / Med-Tech. For more information, please visit our website at beaccelerator.com.tw
The NTUILO was established as a mutual benefitting bridge between the industry and National Taiwan University. It integrates National Taiwan University’s research momentum and provides memberships with National Taiwan University’s cross-sector, cross-industry development technology and talent resources. NTUILO offers memberships with integrated industry-academia co-operation services.

1. NTU is No.1 in Start-Up innovation, Talents competency, R&D capacity, Branding in Taiwan
2. NTU is a complete university with 11 colleges which are all ranked No.1 in Taiwan to provide you with abundant and competitive resources.
3. We adopt Membership system and provide customized service for our corporate members with speed, effectiveness, Networking.

Boston Innovation Capital (BIC) is an advisory firm that was spun out of Life Science Nation (LSN) in 2014 to address an unmet need among early stage scientist-entrepreneurs for tactical, hands-on assistance in packaging management teams and technologies, and executing fundraising campaigns. Traditionally, there are two alternative paths that can be used to address early-stage fundraising needs for life science companies; hire an internal business development executive at a cost of $150k-$250K annually, or find a small-tier investment bank that would be willing to undertake their financing. Boston Innovation Capital was created as a new, more effective and flexible solution to provide this global outreach service, and help new life science technologies take the next step towards the market by augmenting management teams’ outbound campaign initiatives.

Taipei Medical University (TMU) is a collegiate academic institution with an extensive history in Taiwan. Today, TMU has expanded into a world-class university with ten colleges, 6,000 students per year, five hospitals (TMU hospital, Wan Fang Medical Center, Shuang Ho Hospital, Taipei Cancer Center, TMU NingBo medical Center), and more than 40,000 alumni around the world. In terms of development strategy, TMU would construct an interdisciplinary research team by integrating the areas of translational research on cancer, research and development of new drugs, cell therapy, precision medicine, and AI medicine. TMU's vision and goal for future development includes cultivating biomedical talents that are equipped with humanistic empathy, innovative capacity and an international perspective. Also, TMU seeks to link the industry, government and academic to jointly create value and construct a comprehensive medical and nursing service system while crafting a sustainable biomedical platform and ecosystem and becoming a top-tier international university.

The Development Center for Biotechnology, DCB, was founded in 1984 as a non-profit organization based on governmental funds and private donations. DCB’s mission is to facilitate the development of Taiwan’s biotechnology industry by building the infrastructures, developing key biotechnologies, and training and recruiting professional workforces, in coordination with industrial, governmental, academic, and research institutions. DCB, as aiming to act as the “best partner for biotech industry,” plays the role as a “second runner” of value-adding and incubation in the value chain of Taiwan’s biotech-pharma industry. It continues the new drug discovery results of the first-runner research and academic institutions and introduces innovative technology or lead compounds from foreign entities. Via pre-clinical development and value-adding, those achievements are to be transferred to the third-runner biotech-pharma companies where the R&D results are directed to commercialization.
Medmarc was created in 1979 by 31 members of Advamed. Medmarc’s purpose is to be the superior provider of liability insurance, related risk management solutions and to support the development, testing and delivery of medical products that save and improve the quality of lives. Through collaboration with our parent company, ProAssurance, and our clinical trial industry experts, we provide a single source of innovative healthcare liability insurance solutions to the life sciences companies we serve. From ideas and prototypes to the reality of commercialization and success – we can meet your changing needs. Contact us to discuss the cost of insurance coverage and what coverages are needed for your business plan.

The BioMed Commercialization Center is dedicated to translating high-quality academia research into products of great clinical value. Our MedTech team provides companies one-stop support to accelerate through hurdles in commercialization for maximized global value. We provide startup support in value-adding (technology/IP/clinical), prototyping and commercialization. We are setup as a trusted partner for academic and industry clients’ entry into Taiwan’s fast-growing MedTech sectors.

Taiwan Bio Industry Organization (TBIO) established in 1989, is the largest and the most influential biotechnology organization in Taiwan. TBIO represents over 300 members ranging from private companies and academic institutes to government bodies involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology. We are a strong arm to foster the development of biotechnology in Taiwan. Our mission is to provide advocacy, business development, industrial training and communication service for our members. TBIO organizes regular conferences and meetings inviting key industry leaders and government representatives to address members’ interests and concerns. For 2019, TBIO partners with BIO to cohost its annual event under the new name of BIO Asia–Taiwan 2019 and become a true global event. BIO Asia–Taiwan 2020 will be held July 22-26, 2020 in Taipei, Taiwan.

Global Bio & Investment Monthly based in Taiwan, is the professional media platform focus on biotechnology, biopharmaceutical and healthcare industry. We are committed to providing in-depth first-hand information covered the trend of technology, market and investment of biotech industry. We are served as the medium to connect within the industrial value chain. Our vision is to promote the promising health and wealth for global biotech industry.

As one of the top Asia Pacific’s most innovative universities as ranked by Reuters (and ranked 1st in Hong Kong for the 3rd successive years), the Chinese University of Hong Kong (CUHK) is committed to foster innovation partnerships to commercialize our research-derived technologies for the industry and society. Through extensive interdepartmental, multi-disciplinary and international collaborative efforts, CUHK scientists and clinicians aim to deliver research breakthrough to make therapeutic, diagnostic, and clinical research leaps for patients of various diseases. We are sincerely seeking for different partnering opportunities (e.g. Collaborative Research, Registry Development, Patent out-licensing, Clinical Trials, Venture Philanthropy / VC / Early-stage angel investment, etc) for our technologies across therapeutics, diagnostics, medical robotics / imaging and clinical research / trials management.

BioHub Taiwan is a collaborative effort by Academia Sinica, Ministry of Economic Affairs, Ministry of Health and Welfare and Ministry of Science and Technology, who have joined forces in Taiwan’s biomedical development. Our mission is to facilitate and assist the creation, growth, and success of the next generation of biotech companies that will enable start-ups, scientists to nurture early ideas. BioHub Taiwan represents the National Biotechnology Research Park (NBRP) Innovation Incubation Center for international communication and promotion. In this park, we provide state-of-the-art platform technologies for research-driven discovery and drug development, as well as fosters biotech entrepreneurship. Our business interests include: Startup Companies, R&D collaboration, Mentors & Advisory Group, Big Pharma & Clinical Resources, Early stage Investors & Funding Resources.

Venture Valuation specializes in independent assessments and valuations of companies in high-growth markets, such as biotechnology, life sciences and medical technology. Venture Valuation offers independent company valuations for fund raising as well as product valuations for licensing deals.
### Media Partners

<table>
<thead>
<tr>
<th>Media Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FREEMIND</strong> Non-Dilutive Funding Specialists</td>
</tr>
<tr>
<td><strong>Big4Bio</strong></td>
</tr>
<tr>
<td><strong>BioPartner</strong></td>
</tr>
<tr>
<td><strong>Korea Trade-Investment Promotion Agency</strong></td>
</tr>
<tr>
<td><strong>KOTRA</strong></td>
</tr>
<tr>
<td><strong>Japan Bioindustry Association</strong></td>
</tr>
</tbody>
</table>
TAIWANIA
台杉投資

CONNECTING TAIWAN TO THE WORLD

Taiwania Capital Management Corporation is a venture capital firm founded in Taiwan in 2017. We are Taiwan’s national investment arm and backed by resources and support from Taiwan’s government. Our name comes from “Taiwania”, which is one of the largest tree species in Asia that was first discovered in Taiwan more than one hundred years ago and named after Taiwan.

Our goal

is to boost Taiwan’s economic growth by partnering with cutting-edge startups in sectors including:

- ICT
- Biotech
- Material
- Energy
- New Agriculture

Our work

We have launched two funds during 2017-2018.

**Fund I**

NT$ 4.65 billion

- AI
- IoT
- eHealth
- Autonomous Systems
- Enterprise software
- Smart Manufacturing

**Fund II**

NT$ 5.9 billion

- Gene/Cell Therapy
- Medical Technology
- Pharmaceutical Product Research and Development

Taiwania Capital Management Corporation

R.1806,No.333, Keelung Road, Sec.1,Taipei, 11012 Taiwan

Taiwania Capital Management USA, Inc

3945 Freedom Circle, Suite 760, Santa Clara, CA 95054

www.taiwaniacapital.com
### Track 1: Global Investor Panels

#### Moderators & Panelists

9:00 - 9:50 AM  
**Early Stage Therapeutics Investors**  
Bringing the Newest Therapies to the Clinic

- Bill Kohlbrenner, CEO, NeuroLucent  
- Brian Po-Hui Chen, Executive Director, Daiwa Corporate Investment  
- Diana Cheng, Senior Director, Biofund Investment, Taiwania Capital  
- James Huang, Managing Partner, KPCB China/ Panacea Venture  
- Toru Seo, APAC Head & Sr. Director, S&E, Worldwide BD, Chief Business Office, Pfizer

10:00 - 10:50 AM  
**Stetson Family Office**  
Fireside Chat with Global Family Office BioForum

- Grace Mathew, Vice President, Stetson Family Office  
- Dennis Ford, Founder & CEO, Creator of RESI Conference Series, Life Science Nation

11:00 - 11:50 AM  
**Digital Health & AI in Healthcare**  
Cutting Edge Computing Creates New Opportunities for Healthcare Investors

- Arthur Chen, Executive Director, BE Capital  
- John Lin, Investment Director, Abico Asia Capital  
- Benjamin Hu, Vice President - Investments, Foxconn Health Technology Business Group  
- Dennis Lee, Venture Partner, Industrial Technology Investment Corporation  
- Ser-Chen Fu, Partner, Pacific 8 Ventures

1:00 - 1:50 PM  
**Smart Hospital & Homecare**  
Defining the Future of Care Delivery

- Yu-Chuan (Jack) Li - 李友專, 臺北醫學大學醫學科技學院院長  
- Distinguished Professor, Graduate Institute of Biomedical Informatics, CoMST, TMU  
- Dean, College of Medical Science and Technology, Taipei Medical University  
- Chair, Dept. of Dermatology, Taipei Medical University, Wan Fang Hospital  
- Lucy Parkinson, CEO, Boston Innovation Capital; VP, Investor Research, Life Science Nation

2:00 - 2:50 PM  
**Tales from the Road**  
Outside Taiwan Entrepreneurs Talking about Successful Partnerships with Taiwan

- Greg Mannix, VP of International Business Development, Life Science Nation  
- Amit Vohra, CEO, Promaxo  
- Daria Lemann Blumenthal, CEO, BELKIN Laser  
- John Gregg, CEO, Balinbac Therapeutics  
- Michel Chu, CEO, VSense

3:00 - 3:50 PM  
**Medical Device & Diagnostics**  
Investing in Novel Engineering & New Generation of Technologies Changing Treatment Paradigms

- Greg Mannix, VP of International Business Development, Life Science Nation  
- Dale Yakin, Senior Advisor, VelocityHealth Securities, Inc  
- David Ong, Investment Manager, Lucima Gruppo  
- David Uffer, Senior Partner, VP of MedTech, Alira Health  
- Michel Chu, General Partner, Acorn Campus Taiwan
This panel aims to bring a diverse group of experts & senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:

- How they make decisions
- What can startups do to be more attractive?
- Areas of high need
- Overcrowded areas
- Common mistakes/red flags

The moderator will guide the discussion through topics including how the investors source & vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.

- **Bill Kohlbrenner, CEO, NeuroLucent**
  Dr. Kohlbrenner is currently Chief Scientific Officer at Life Science Nation (LSN) and is Consulting Scientist for Boston Innovation Capital. In addition, he is CEO of NeuroLucent, a Chicago-based company working on Alzheimer’s disease. Prior to joining LSN, Bill was a director at AbbVie, where he led a global scouting team and conducted strategic assessments of early- and late-stage pipeline opportunities. Earlier in his career, Bill led drug discovery research programs in oncology, antivirals and antibacterials. Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.

- **Brian Po-Hui Chen, Executive Director, Daiwa Corporate Investment**
  Dr. Chen joined Daiwa Corporate Investment (DCI) group in 2015, together with DCI/DCI partners (DCIP) teams to establish and manage the TW-JP bio fund, including raising the fund, investment, and post-investment value-adding management, with active participation in the biomedical industry. Before joining DCI, Dr. Chen used to work for Nankang Biotech Incubation Center (NBIC), Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), Development Center for Biotechnology (DCB). Acting as a BD director completing important projects such as CTPS department transaction and BPFF spin-off, Dr. Chen is familiar with corporate development, investment, event organization, industry promotion. Not only in biotech industry, Dr. Chen is also experienced in equity investment and acting as important roles in diversified professional societies and industries such as CFA Society Taiwan and MJ Taiwan, with extensive network and capability of cross-border integration.

- **Diana Cheng, Senior Director, Biofund Investment, Taiwania Capital**
  Diana Cheng, possesses passion and hands-on experience in various pharmaceutical topics, including new drug development, clinical trials management, life cycle strategies, particular in MSL development/management and local/regional medical affairs activities within Asia-Pacific. Her previous therapeutic area of expertise ranged across oncology, neurology, ophthalmology, cardiovascular diseases, infectious diseases, HIV, and Vaccines. Serving as Senior Investment Director in Taiwania Capital—a venture capital firm backed by Taiwan Development Council, Diana is responsible for due diligence activities and provides critical support to the portfolio companies. She committed to contribute and build the developing biotech ecosystem in Taiwan. In the longer term, Diana envisions herself to lead and be involved in more critical resource allocation decisions in the Global R&D, commercialization, business development, licensing, and alliance management, where she thinks the greatest impact to be made to improve human healthcare. Diana holds an MBA in Finance and Healthcare Management from Columbia Business School in the New York City and a MD from National Taiwan University.

- **James Huang, Managing Partner, KPCB China/ Panacea Venture**
  James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Before coming to KPCB China, James was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007, James was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. Meanwhile, James Huang is also founding and Managing Partner to Panacea Venture. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide, is established and managed by experienced partners Mr. James Huang whom is KPCB China’s managing partner. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

- **Toru Seo, APAC Head and Sr Director, S&E, Worldwide BD, Chief Business Office, Pfizer, Inc.**
  Dr. Toru James Seo is a Senior Director and APAC head of scout and Evaluation, Worldwide Business Development, Chief Business Office, Pfizer Inc. He obtained his Ph.D in Molecular and Cellular Pathology from Wake Forest University and joined the faculty as an assistant professor in Department of Pediatrics at Columbia University Medical Center. In 2006, he moved to pursue a R&D career in the pharma industry such as GSK, MERCK and TAISHO where his roles grew to include project leader, global scientific committee member and team lead, and later, in business development and corporate strategic planning. In 2015, he joined Pfizer Inc. as a Japan head of External Science and Innovation (ESI) before assuming his current position in 2019 to oversee search/scouting activity of innovative and breakthrough drug candidates in APAC regions. Outside of Pfizer, he is an advisory committee of Osaka University and a visiting professor of Waseda Business School, Waseda University. He is also active as an external counselor and advisors of a few biotechs and VC including Biolite Japan which he founded and function as an advisor.
This Fireside Chat provides a great opportunity to network with other family offices that focus on life sciences or healthcare investment and hear firsthand the global early stage funding initiatives that the Stetson Family Office is involved with. Those include the Healthcare Impact Foundation established in 2017, The Global Family Office BioForum (GFOB) - the leading alliance of international Family Offices focused on healthcare/life science which meets quarterly in 18 cities in the US, Europe and Asia, and the joint partnership with Life Science Nation and the RESI Conference Series. These initiatives aim to assist the earliest stage life sciences companies by sourcing seed capital and management talent.

**Grace Mathew, Vice President, Stetson Family Office**

Selected as one of Australia’s 100 Brightest Young Minds in 2010, Grace has applied her strengths in communication, leadership, and relationship management to roles in the corporate and not-for-profit sectors, regularly presenting to audiences of up to 60,000 since age 15. She was awarded the Goldman Sachs Global Leader Award in 2008, in recognition of achievements in the community and international leadership initiatives. While earning her Bachelor of International & Global Studies and Master of International Relations from the University of Sydney, Grace also completed postgraduate courses in Political Science at George Washington University in Washington, DC, and Leadership at Sydney’s Alphacrucis College. As one of three scholarship recipients to attend the Global Leadership Institute in New York, she represented Australia, engaging with key political, corporate and philanthropic leaders at the United Nations. Grace’s experience ranges from raising funds for philanthropic organizations such as UNICEF, to helping lead, organize, and MCing events with over 10,000 attendees. As a freelance writer and on-camera presenter, she has been published in magazines such as The Journal, Family Office Magazine, and Christian Today, and hosted on-camera interviews for BuildCurious and The Jerusalem Peace Project, amongst others. Grace is currently Managing Director of third-generation US family office Stetson Family Office. She is developing a global education initiative, and working on a campaign to deliver better healthcare outcomes at lower costs, in association with the Global Partnerships Forum, Healthcare Impact Foundation, and United Nations Sustainable Development Goals. Grace also consults on business strategy, culture, and negotiation, as Chief Strategist of WeThink, where she designs and leads commercial and philanthropic ventures to generate positive social outcomes.

**Dennis Ford, Founder & CEO, Creator of RESI Conference Series, Life Science Nation**

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. He has spent most of his career involved in launching new technology-based companies. He has wide-ranging experience in hardware and software computing, middleware, data storage, networking, SaaS, data mining, data profiling, expert systems, and scaling/funding companies. Most recently, Dennis has spent the last 7 years in the early-stage life science arena creating an ecosystem to streamline fundraising for next-generation drugs, devices, diagnostics, and digital health products. Currently, Life Science Nation has the most comprehensive life science investor database in the world. Dennis has also pioneered a unique global partnering event model that matches buyers and sellers based on their specifically stated needs and declared partnering mandate initiatives garnered from one-on-one interviews and curating buyer/seller databases in a selected industry. Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto, which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO’s which is now offered to international government agencies to move their funded startups into the global funding arena.
This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, and on the many applications of AI in Healthcare. These can range from changing how care is delivered or managed, to personalized diagnostics available to clinicians and patients. Panelists will explore topics related to investing in digital health and AI applications, including:

- In what kinds of technologies are they interested in investing?
- What metrics and evidence do you look for in a digital-based technology startup?
- How can an early stage digital health/AI company demonstrate the value of their products?
- What are the main challenges for startups raising capital in this space?

The moderator and panelists will discuss this rapidly evolving field of digital health and AI in the field of healthcare. In addition, panelists can discuss the risks associated with such new technology where the regulatory pathway is not yet clearly defined.

**Arthur Chen**, Executive Director, BE Capital

A serial entrepreneur and venture capitalist, Arthur works as the Executive Director at BE Capital a healthcare focused investment firm, where he manages and invests a portfolio of medical technology ventures in the USA and Greater China. Meanwhile, he is also an impact investor at Rookie Fund and #43 Ventures, with strong dedication to supporting youth entrepreneurship. Arthur received his EMBA from Columbia and London business Schools, and is taking Stanford GSB’s Innovation and Entrepreneurship Certificate Program. He is also an amateur Jazz sax and basketball lover.

**John Lin**, Investment Director, Abico Asia Capital

John Lin is an investment director with Abico Asia Capital, based in Taipei. John is experienced in identifying investment and buyout ideas within the healthcare and electric vehicle sectors, and managing investments on an end-to-end basis. He is committed to increase enterprise value with local networks and regional resource and has closed deals across Japan, China, ASEAN and Taiwan. Prior to joining Abico Asia Capital in 2017, he spent 3 years in CDIB capital group. He is also active in startup community, as Venture Consultant of Taipei City Government of Taiwan, he advises founders and executives on top-management level topics including fundraising, corporate strategy, mergers and acquisitions. John holds a MBA from National Chengchi University.

**Benjamin Hu**, Vice President - Investments, Foxconn Health Technology Business Group

Ben serves as the Head of Investment for Foxconn’s Health Technology Group, overseeing venture investment, corporate development, and portfolio management for Foxconn’s efforts in healthcare and the life sciences. Key interests include digital health, connected devices, genomics, and molecular diagnostics. Previously, Ben was a Vice President at WI Harper Group – an early-stage venture capital firm, working out of the San Francisco and Taipei offices, where he sourced and managed investments in both healthcare and technology sectors. Ben was born and raised in Silicon Valley. He holds a Bachelor of Science from Cornell University in Genetics and Bioengineering Technology, and attended / dropped out of UC San Diego’s MD/PhD program. He’s a big believer in entrepreneurs, and curious about almost anything.

**Dennis Lee**, Venture Partner, Industrial Technology Investment Corporation

Return to Taiwan from the Bay Area. And started Studio88 Design Corp, a MedTech Design Consulting Firm in 2013. Specialize in Innovative Medical Device’s Product-Market Fit of Asia Pacific, Europe, and North America. Believer of Lean Startup launchpad, practice Evidence- Based Design and work closely with International Medical Device Manufacturers and International Medtech Startups to develop their innovative solutions. Step into the early-stage investments focus on evaluating combination of Clinical and Business Unmet Needs in Healthcare Ecosystem.

**Ser-Chen Fu**, Partner, Pacific 8 Ventures

Dr. Ser-Chen Fu was previously trained as a clinical neurologist and served as an attending physician during his clinical practice. At Pacific 8 Ventures, he provides a clinical and medical perspective in assisting healthcare startups realize their visions. Experience: Tzu-Chi University Medical School; Neurology Resident, Chang-Gung Memorial Hospital; Attending Physician, Taipei Tzu-Chi Hospital; Attending Physician, Hualien Tzu-Chi Hospital
The Smart Hospital concept is aimed at creating a single IT environment composed of automated specialized and auxiliary processes. Thanks to new technological revolutions, a huge amount of data, cloud computing services, machine learning methods, and artificial intelligence (AI) solutions can be combined. AI has the potential to have a transformative impact on the healthcare field, and the coalescence of medical equipment into the network has already changed the methods of work in the healthcare industry. By 2020, the widespread introduction of high-tech methods in medicine will begin the implementation of the smart hospital project. It is estimated that by 2024 smart hospital market will be worth USD 63 billion.

This talk will describe some of the most important AI applications in hospital and homecare:

• How will AI impact care quality and patient safety?
• Will AI enable earlier detection of diseases?
• Will AI mean care delivery can become truly personalized?

We will also discuss how Big Data and AI will go hand-in-hand in the future of health care for all the stakeholders, in terms of high-performance healthcare and precision medicine.

• **Yu-Chuan (Jack) Li** - 李友專 臺北醫學大學醫學科技學院 院長

Distinguished Professor, Graduate Institute of Biomedical Informatics, CoMST, TMU

Dean, College of Medical Science and Technology, Taipei Medical University

Chair, Dept. of Dermatology, Taipei Medical University, Wan Fang Hospital

Prof Dr. Yu-Chuan (Jack) Li has been a pioneer of Medical Informatics research in Asia. He served as a Vice President of Taipei Medical University (TMU) (2009-2011) and currently, he has been the Dean of College of Medical science and Technology since 2011 and Distinguished Professor of the Graduate Institute of Biomedical Informatics since 1998. He obtains his M.D. from TMU in 1991 and his PhD in Medical Informatics from University of Utah in 1994. Due to his achievement in establishing EHR exchange models among hospitals and his dedication to IT applications in patient safety and care, he was awarded as one of the Ten Outstanding Young Persons of the Year in 2001. He has been Principal Investigator of many national and international projects in the domain of Electronic Health Record, Patient Safety Informatics and Medical Big Data. He is author of 130 scientific papers and 3 college-level textbooks. He became an elective fellow of American College of Medical Informatics (FACMI), (2010), Australian College of Health Informatics (FACHI), (2010), founding members of International Academy of Health Sciences Informatics (IAHSI), (2017) and also the President of Asia Pacific Association for Medical Informatics (APAMI) from 2006 to 2009. In recent five years, he was the Editor-in-Chief of two internationally renowned journals - Computer Methods and Programs in Biomedicine and International Journal for Quality in Health Care. The most honored about is recently he become elective president of IMIA(International Medical Informatics Association). His main areas of expertise are: AI in Medicine, Patient Safety Informatics, and Medical Big Data Analytics.

• **Lucy Parkinson**, CEO, Boston Innovation Capital; VP, Investor Research, Life Science Nation

Lucy Parkinson is CEO of Boston Innovation Capital and VP of Investor Research, leading LSN’s investor outreach and analysis team. In over five years as an employee of both Life Science Nation and Boston Innovation Capital, she has analyzed global investors and channel partners in depth and determined which have vetted mandates and are a fit for her clients. She leads a team of global investor research analysts that curate the LSN Investor Platform, which tracks 10 categories of early-stage life science investors across the silos of drugs, devices, diagnostics and digital health. Lucy also runs the programming of LSN’s Redefining Early Stage Investments (RESI) Conference Series, which hosts about 2000 investors annually. She was a contributing writer for The Life Science Executive’s Fundraising Manifesto and to two articles published in Nature Bioentrepreneur, as well as being a frequent contributor to LSN’s Next Phase weekly newsletter. Prior to joining LSN, Lucy spent several years working at CPA firms, gaining experience working with small corporations, partnerships and non-profit organizations. Lucy graduated from the University of Leeds with a degree in the History and Philosophy of Science. She is a FINRA-registered securities representative and principal, holding Series 7,24, and 63 registrations.
This panel brings together biotech and medtech entrepreneurs to tell their stories of raising capital. You’ll hear their firsthand accounts of navigating the fundraising process and raising capital. Topics may include:

- What stumbling blocks had they hit?
- How had they solved the issues, and what had they learned about raising capital?
- How did they go about finding potential investors, and how did they determine which investors they should pursue?

---

**• Greg Mannix, VP of International Business Development, Life Science Nation**

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to successfully fundraise and to facilitate cross-border investments, licensing and M&A transactions.

---

**• Amit Vohra, CEO, Promaxo**

Dr. Amit Vohra is a serial entrepreneur, business strategist and advisor to several healthcare and technology startups. He is the Co-Founder of Promaxo and currently serves as the Company’s President & Chief Executive Officer. Amit is a Partner in Advanced Biopharma Consulting, a management consultancy offering strategic business development and commercialization services in the life sciences space. He is a Board Member at Navaux, and a West Coast Advisory Board Member for the Herbert Wertheim College of Engineering at University of Florida. Previously, at Eigen, he led the successful commercialization of two class II medical devices in urology. Amit has a Doctorate in Mechanical Engineering from University of Florida, and an MBA from Duke University’s Fuqua School of Business.

---

**• Daria Lemann Blumenthal, CEO, BELKIN Laser**

Daria joined BELKIN in 2013 and was previously CEO of the Ein Tal Eye Center for 6 years. She has extensive managerial experience, including business development, project management, and team leadership. Mrs. Lemann-Blumenthal completed her LL.B. at the Hebrew University in Jerusalem and an Executive MBA at Tel-Aviv University, both degrees awarded with Dean’s Honors.

---

**• John Gregg, CEO, Balinbac Therapeutics**

Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting microbiome companies for investors. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). He has spent much of his career directing the commercialization efforts for a large number of antibiotic, anti-protozoal, anti-fungal and anti-viral drugs as well as therapeutics in multiple other therapeutic areas, including immunology and oncology. He is an industry leader in biotech company development, serving as CEO of specialty infectious disease and microbiome modulation companies like his current company, BalinBac (Balance in Bacterial Species) Therapeutics, and his prior microbiome start-up, Symbiomix Therapeutics.

---

**• Michel Chu, CEO, VSense**

Michel Chu is a serial entrepreneur, investor, mentor, adjunct professor and entrepreneurial coach. Michel is currently General Partner of Acorn Campus Taiwan, a venture fund focusing on early-stage life science opportunities. In addition, Michel also serves, on volunteer basis, as the Chief Innovation Officer of BioMedTW – Taiwan government’s task force to oversee, facilitate and accelerate Taiwan’s life science industry. Michel co-founded GigaMedia (NASDAQ: GIGM) in 1997 and led the company through a $4.5B IPO in 2000. Michel has extensive domain expertise in diverse fields from medical devices, mobile Internet, cloud computing to merger and acquisitions. Michel has been an active early-stage investor with 15+ years of experiences of coaching, building, inspiring and accelerating entrepreneurial teams.
This panel focuses on investments in innovative diagnostics and medical devices, ranging from IVD, imaging technologies, surgical tools, connected devices and more. Topics may include:

- What are investors looking for? - Areas of interest - Overcrowded areas
- Current challenges in this ecosystem
- Navigating the competitive landscape
- Commonly observed red flags
- How to approach an investor

Panelists will discuss how companies can successfully fundraise for their budding technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

• **Greg Mannix**, VP of International Business Development, *Life Science Nation*  
  Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg's role at LSN is to provide international early-stage companies with the tools and strategies to successfully fundraise and to facilitate cross-border investments, licensing and M&A transactions.

• **Dale Yakin**, Senior Advisor, *VelocityHealth Securities, Inc*  
  Mr. Yakin is a Managing Director for VelocityHealth Securities where he is focused on the life sciences including the diagnostic sector. He began working with VelocityHealth in 2013 from his base in Taiwan where he maintains close ties with a network of industry contacts throughout the Asia-Pac region and concentrates on identifying opportunities for cross-border deals. Previously, he held several positions within Novartis, the last role being Head BPA for the Diagnostics division's APAC commercial organization based in Hong Kong. He had initially joined Novartis in 2006 with key responsibilities in the areas of M&A valuation, partnering, strategic and capital planning. Mr. Yakin holds a MS in Engineering and an MBA.

• **David Ong**, Investment Manager, *Lucima Gruppo*  
  LUCIMA GRUPPO is an international investment firm based in Taipei, Taiwan. Our current healthcare and medical device portfolio includes Suntop Healthcare Corporation, a provider of hemodialysis service in China, and AcuSolutions, a developer of optical sectioning device being tested in UCSF. Prior to joining LUCIMA GRUPPO, David worked at SinoPac Venture Capital (Taipei) and Tripod Capital (Beijing). Before venturing into investments, David was an interventional cardiologist in Peking University First Hospital and was responsible for pre-clinical/clinical study of innovative coronary stent. David holds a MD from Peking University and a MBA from Vierick Business School.

• **David Uffer**, Senior Partner, VP of MedTech, *Alira Health*  
  David Uffer joined Alira Health with over 25 years of management experience in the medical device, products and clinical diagnostics field. He has lead strategy development, strategic planning and business development activities in these fields for mid and large cap public companies. David has directed business development deals ranging from M&A, licensing, distribution and co-development for companies such as Medtronic (legacy Covidien) in their respiratory and medical products business, as well as Hologic and Boston Scientific. He has held management roles at Integra Lifesciences and Abbott Labs. David has a BA from Clark University, Worcester, MA and an MBA from Thunderbird, School of Global Management, Glendale, AZ.

• **Michel Chu**, General Partner, *Acorn Campus Taiwan*  
  Michel Chu is a serial entrepreneur, investor, mentor, adjunct professor and entrepreneurial coach. Michel is currently General Partner of Acorn Campus Taiwan, a venture fund focusing on early-stage life science opportunities. In addition, Michel also serves, on volunteer basis, as the Chief Innovation Officer of BioMedTW – Taiwan government's task force to oversee, facilitate and accelerate Taiwan’s life science industry. Michel co-founded GigaMedia (NASDAQ: GIGM) in 1997 and led the company through a $4.5B IPO in 2000. Michel has extensive domain expertise in diverse fields from medical devices, mobile Internet, cloud computing to merger and acquisitions. Michel has been an active early-stage investor with 15+ years of experiences of coaching, building, inspiring and accelerating entrepreneurial teams.
Global Bio & Investment
Biomedical and Pharmaceutical News, Photos, and Stories for Chinese Readers

Website × Facebook × LINE@ × Youtube

- Daily Bio News
- Latest Market Information
- Features & In-depth Coverage
- Live News Feed
- Events Update
- Bio Industry Connections
- Daily Bio News
- One-on-one Chats
- Exclusive Offers
- CEO Interviews
- Live Video

Contact: Stoven Lai
TEL: +886 2-2726-1065 ext.11
E-Mail: stoven.lai@gbimonthly.com

Subscribe to E-magazines

www.gbimonthly.com
www.facebook.com/gbimonthly/
Follows us on LINE @wbo9725c
goo.gl/TrHfSU

Youtube Channel
goo.gl/TrHfSU
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:50 AM</td>
<td><strong>FUNDRAISING BOOTCAMP</strong></td>
<td>• Dennis Ford, Founder &amp; CEO, Creator of RESI Conference Series, <em>Life Science Nation</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Greg Mannix, VP of International Business Development, <em>Life Science Nation</em></td>
</tr>
<tr>
<td>10:00 - 10:50 AM</td>
<td><strong>BRANDING &amp; MESSAGING</strong></td>
<td>• Dennis Ford, Founder &amp; CEO, Creator of RESI Conference Series, <em>Life Science Nation</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Greg Mannix, VP of International Business Development, <em>Life Science Nation</em></td>
</tr>
<tr>
<td>11:00 - 11:50 AM</td>
<td><strong>INTERNATIONAL COLLABORATION</strong></td>
<td>• Lily Wong, Partner, <em>PricewaterhouseCoopers Taiwan Deals Services, Taiwan Health Industry Leader</em></td>
</tr>
<tr>
<td>1:00 - 1:50 PM</td>
<td><strong>GLOBAL COLLABORATION TRENDS IN LIFE SCIENCE &amp; HEALTHCARE SECTORS</strong></td>
<td>• Michelle Gon, Partner, <em>McDermott Will &amp; Emery, Shanghai</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dale Van Demark, Partner, <em>McDermott Will &amp; Emery, Washington DC</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Emmanuelle Trombe, Partner, <em>McDermott Will &amp; Emery, Paris</em></td>
</tr>
<tr>
<td>2:00 - 2:50 PM</td>
<td><strong>KEY ISSUES ON CROSS BROADER TRANSACTIONS IN THE LIFE SCIENCE &amp; HEALTHCARE SECTORS</strong></td>
<td>• Michelle Gon, Partner, <em>McDermott Will &amp; Emery, Shanghai</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Byron Kalogerou, Partner, <em>McDermott Will &amp; Emery, Boston</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Emmanuelle Trombe, Partner, <em>McDermott Will &amp; Emery, Paris</em></td>
</tr>
<tr>
<td>3:00 - 3:50 PM</td>
<td><strong>CHALLENGES AND OPPORTUNITIES – IP DEVELOPMENTS IN LIFE SCIENCES</strong></td>
<td>• Michelle Gon, Partner, <em>McDermott Will &amp; Emery, Shanghai</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sarah Columbia, Partner, <em>McDermott Will &amp; Emery, Boston</em></td>
</tr>
</tbody>
</table>
When investment meets innovation

PwC Taiwan leads you to a morning session at RESI Taipei 2019 on 14 November, focusing on the latest trends in biotech innovation and investment, ranging from angel/VC investments for early-stage entrepreneurs to capital markets, IPO listing and M&A activities for more mature biomedical companies.

Venture capital investments  Mergers and acquisitions

Capital markets and IPOs

www.pwc.tw/bio
Join PwC’s scale-up post-accelerator
LSN - Fundraising Bootcamp ; Branding & Messaging Workshop

- **Dennis Ford**, Founder & CEO, Creator of RESI Conference Series, *Life Science Nation*
  Dennis Ford is an entrepreneur, author, and front-end technologist with deep expertise in sales, marketing, and business development. He has spent most of his career involved in launching new technology-based companies. He has wide-ranging experience in hardware and software computing, middleware, data storage, networking, SaaS, data mining, data profiling, expert systems, and scaling/funding companies. Most recently, Dennis has spent the last 7 years in the early-stage life science arena creating an ecosystem to streamline fundraising for next-generation drugs, devices, diagnostics, and digital health products. Currently, Life Science Nation has the most comprehensive life science investor database in the world. Dennis has also pioneered a unique global partnering event model that matches buyers and sellers based on their specifically stated needs and declared partnering mandate initiatives garnered from one-on-one interviews and curating buyer/seller databases in a selected industry. Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto, which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO’s which is now offered to international government agencies to move their funded startups into the global funding arena.

- **Greg Mannix**, VP of International Business Development, *Life Science Nation*
  Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to successfully fundraise and to facilitate cross-border investments, licensing and M&A transactions.

PwC - International Collaboration Workshop

**Workshop Outline:**
1. Industry at a glance
2. Potential collaboration model
3. Collaboration cases

- **Lily Wong**, Partner, PricewaterhouseCoopers Taiwan; Deals Services, *Taiwan Health Industry Leader*
  Lily Wong is a partner with the Deals Services practice and health industry leader in Taiwan, specializing in providing acquisition and merger advisory and strategic consulting services. Lily has led/managed several buy-side advisory projects for both strategic and financial buyers as well as advised clients in a number of carve-outs and vendor assistance. In addition, Lily has led several market assessment and commercial due diligence works for foreign investors entering into Taiwan markets. Lily is a Certified Treasury Professional in the US and also holds CPA licenses for both the US and Taiwan. Lily obtained her Master of Accounting Science degree from the University of Illinois and her Bachelor of Business Administration degree from National Taiwan University. Her recent deal experiences and advisory experiences in biotech and healthcare sector include:
  - Led a white paper project on Taiwan healthcare system for an MNC association
  - Led a number of market access projects for a leading multinational drugmaker on its long-range vision lead and specialty drug entry
  - Conducted market assessment on Taiwan healthcare sector including service providers, senor services, pharmaceutical, biotech and medical device industries
  - Provided lead advisory services to a medical beauty chain and a foreign medical device company for seeking strategic and financial investors in developing greater China business
  - Provided valuation services to several biopharmaceutical companies in Taiwan
  - Provided financial due diligence services to a leading global group in the proposed acquisition of a Taiwanese biotech company specialized in biosimilars related products/services
  - Provided financial due diligence and valuation advisory services to a leading TWSE-listed pharmaceutical company in the proposed equity investments in US and China pharmaceutical companies

---

**Track 2 - Morning**

**Entrepreneur Workshops**

**PwC - International Collaboration Workshop**

**Features & In-depth**

- Daily Bio News
- Exclusive Offers
- Live News Feed
- One-on-one Chats
- Events Update
- Bio Industry Connections
- Live Video
- CEO Interviews
- Bio Industry Insights
- Bio Industry Development
- Bio Industry Science
- Bio Industry News
- Bio Industry Events
- Bio Industry Tools
- Bio Industry Resources
LOOKING FOR A LIFE SCIENCES INDUSTRY MARKET SPECIALIST?

Ward’s 50* Top Insurance Company
A.M. Best A+(Superior) Rating
Industry Specialists Since 1979
AdvaMed’s Exclusive Provider for
Preferred Insurance and Risk Management
Products Liability and E & O Liability
Clinical Trials Liability
Worldwide Coverage

Medmarc provides insurance protection to the following manufacturers and distributors:

Medical Devices | Animal Health Care
Pharmaceuticals | Biotechnology
In Vitro Diagnostics | Personal Hygiene

800.356.6886 Medmarc.com
Find all the answers in one place.
Contact George Ayd 703-652-1360 | gayd@medmarc.com

ABOUT THE BOOK

A primary objective for life science executives is raising capital. Very often, however, a lack of marketing and sales skills impedes their efforts. Focusing regionally, rather than globally, only compounds the challenge.

The Life Science Executive’s Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies, using a consistent message to achieve compelling results from a fundraising campaign. It teaches you how to aggregate a list of potential global investors that are a fit for your company’s products and services. Then it explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.

Raising capital is not a one-time event. It must be an ongoing part of your business strategy. The Life Science Executive’s Fundraising Manifesto reveals the expertise required to continually fundraise and bring your ideas to market.

FOR MORE INFORMATION

Visit www.FundraisingManifesto.com
or visit the Life Science Nation table at the exhibit hall
• Michelle Gon, Partner, McDermott Will & Emery, Shanghai

Michelle Gon is a partner of McDermott Will & Emery, stationed at MWE China Law Offices in Shanghai. Her practice focuses on compliance and regulatory matters, including anti-corruption, unfair competition, anti-monopoly, anti-fraud representations, anti-fraud and economic sanction areas. With her long term, on-the-ground experience of doing business both within and outside China, she provides practical advice to clients on complex cross broader legal issues. Michelle was named as one of the Top 30 Attorneys in China by Asian Legal Business in 2004. She was listed as a leading lawyer in the life sciences sector by Chambers Asia Pacific in 2012, 2013, 2014 and 2015. Michelle was ranked as a Corporate Investigation and Anti-bribery Spotlight Table of Foreign Legal Consultants China by Chambers Asia Pacific 2017 & 2018. Michelle is a member of the Illinois State Bar Association. She has lectured at Tsing Hua University for its international EMBA programs for several years. Michelle is the organizer for McDermott’s annual event on China Life Science and Healthcare Outbound Legal Symposium. She works closely with LSN and Stetson Family Office on the First RESI Conference in Shanghai and Taipei.

• Dale Van Demark, Partner, McDermott Will & Emery, Washington DC

Dale C. Van Demark advises clients in the health industry on strategic transactions and the evolution of health care delivery models. He has extensive experience in health system affiliations and joint venture transactions. Dale also provides counseling on the development of technology in health care delivery, with a particular emphasis on telemedicine. Dale has been at the forefront of advising clients with respect to the globalization of the US health care industry. He advises US and non-US enterprises with respect to the formation of cross-border affiliations and international patient programs. In addition to writing regularly on matters related to his practice, Dale has spoken at numerous conferences around the world on the globalization of health care. He is also a member of our legal cannabis industry group. Our Cannabis Industry group is a multidisciplinary team of lawyers providing clients with regulatory, litigation, intellectual property, trade and tax services with respect to their investments and participation in the cannabis industry, all subject to the Firm’s obligations under federal and state laws and bar licensure rules.

• Emmanuelle Trombe, Partner, McDermott Will & Emery, Paris

Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnering, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded.

• Byron Kalogerou, Partner, McDermott Will & Emery, Boston

Byron S. Kalogerou is the Chair of the Firm’s Life Science Industry Group and head of the Boston Corporate Advisory Practice Group. Byron focuses his practice on domestic and cross border mergers and acquisitions, corporate finance and joint ventures and alliances. He has substantial on the ground experience in structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the medical device, fire and security, energy, telecom and industrial sectors. Before his move back to private practice, Byron spent 17 years in-house, including 14 years at Tyco International, where he served in a variety of roles including as general counsel of its fire and security business, its telecommunications business and as general counsel of its international legal department, a function he created. He has handled hundreds of M&A transactions. These include Tyco’s most significant transactions, including the $12 billion acquisition of AMP Inc., the $850 million purchase of AT&T Submarine Systems, and the $2.2 billion initial public offering of TyCom Ltd. In addition, he handled many of Tyco’s medical device company acquisitions.

• Sarah Columbia, Partner, McDermott Will & Emery, Boston

Sarah Chapin Columbia is a Fellow in the American College of Trial Lawyers. Over the last nine years, she has led 14 patent infringement and invalidity trials (eight jury trials, six bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, California and Texas. Sarah also counsels clients on overall intellectual property strategy and positioning, including litigation avoidance. She provides legal services across several industries, including semiconductor, pharma/biotech, internet, hardware and software, medical device and manufacturing companies. Sarah is a member of the faculty of the Munich Intellectual Property Law Center, where each year she teaches a two-day course focused on US patent litigation.
FUEL MISSIONS.  
KNOCK DOWN BARRIERS.  
SHAPE MARKETS.

We’re proud to help propel the success of the world’s most respected, dynamic and important organizations. Our dedicated lawyers combine their passion for business with a deep understanding of the law to deliver the insights and results that matter to your business and to the people you serve.

LEARN MORE AT MWE.COM AND MWECHINA.COM
Taipei Medical University Global Research & Industry Alliance (TMU GLORIA) is committed to creating and strengthening mutually beneficial collaboration between academic/clinical professionals and corporation partners worldwide.

**Focus Areas**
- Artificial Intelligence in Medicine
- Smart Healthcare
- Precision Medicine
- Translation Medicine
- Medical Device Discovery
- New Drug Discovery

**Linking Universities with Industries**
Satisfying industries' needs with the provision of one-stop services from universities

**Services**
- Industry-university Collaboration
- Business Opportunities
- Talents
- Technical Consultancy
- Laboratory Sharing
- Conference
- Database Sharing

**Contact Us**
http://gloriabiomed.tmu.edu.tw
Email: gloriabiomed@tmu.edu.tw
Office Hour: 9:00AM-6:00PM (Mon-Fri)
Address: 20F, No. 172-1, Sec. 2, Keelung Rd., Da’an Dist., Taipei City 10675, Taiwan
**Track 3**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Finalists</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:50 AM</td>
<td>PITCH SESSION 1</td>
<td>MEDICAL DEVICE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BELKIN, CYOTENER, NAVI, promaxo, CLEARFLOW</td>
</tr>
<tr>
<td>10:00 - 10:50 AM</td>
<td>PITCH SESSION 2</td>
<td>MIX OF THERAPEUTICS, DIAGNOSTICS, DIGITAL HEALTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CytoArm, ATP, GuZap, AESOP</td>
</tr>
<tr>
<td>11:00 - 11:50 AM</td>
<td>PITCH SESSION 3</td>
<td>THERAPEUTICS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Allgenesis, GRI BIO, BalinBac, CHARSIRE, TERRAN BIOSCIENCES</td>
</tr>
<tr>
<td>1:00 - 1:50 PM</td>
<td>PITCH SESSION 4</td>
<td>MIX OF THERAPEUTICS, DIAGNOSTICS, DIGITAL HEALTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alpha6GABA, Bluesense Diagnostics, AHEAD, VSense, Reliance Biosciences</td>
</tr>
<tr>
<td>2:00 - 2:50 PM</td>
<td>PITCH SESSION 5</td>
<td>MEDICAL DEVICE &amp; DIAGNOSTICS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Geoll, OneTest, Carmentix, NZ technologies Ltd.</td>
</tr>
<tr>
<td>3:00 - 3:50 PM</td>
<td>PITCH SESSION 6</td>
<td>THERAPEUTICS &amp; DIGITAL HEALTH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Huijia, Jello, Conzian, Kupando</td>
</tr>
</tbody>
</table>
We Connect Business

NTU in leading position in several territories in Asia

ABOUT US

The NTUILO was established as a mutual benefitting bridge between the industry and National Taiwan University. It integrates National Taiwan University’s research momentum (currently consisting of 11 colleges and 3 professional colleges, 5 international, 7 national and 46 institute level research centre) and provides memberships with National Taiwan University’s cross-sector, cross-industry development technology and talent resources.

WHY US?

1 - Collaboration With Taiwan’s Industry & Academia with speed, effectiveness, Networking.

2 - NTUILO consists of Industry Experts who have more than 20 years experience in different industries

3 - We adopt Membership system and provide customized service for our corporate members
The RESI Taipei Pitch Sessions gives all RESI Innovation Challenge Finalists an opportunity to pitch to a panel of early stage investors. The finalists were selected by LSN’s Expert System and scientific review team to present their technology through a 4-minute pitch. Investors will provide feedback and questions to the pitching CEOs.

- **Angus McQuilken**, Industry Relationship Executive - Life Sciences, McDermott Will & Emery, Boston
  Angus McQuilken serves as Vice President for Business Development and Public Affairs for LaVoieHealthScience, a Boston-based firm that provides strategic communications programs integrating public and investor relations, marketing and communications. From 2008-2017 McQuilken served as Vice President for Communications & Marketing for the Massachusetts Life Sciences Center, the agency charged with implementing Massachusetts’ ten-year, $1 billion Life Sciences Initiative, where he served as part of the start-up and executive management teams. From 2004-2008 he focused on health care communications and advocacy while serving as Vice President for Public Affairs for Planned Parenthood League of Massachusetts. McQuilken has also served as Chief of Staff for Massachusetts State Senator Cheryl Jacques, and as Deputy Communications Director for the Democratic National Convention Committee. McQuilken is an adjunct faculty member at Lasell College, where he teaches courses focused on both public relations and public speaking.

- **Benjamin Hu**, Vice President - Investments, Foxconn Health Technology Business Group
  Ben serves as the Head of Investment for Foxconn’s Health Technology Group, overseeing venture investment, corporate development, and portfolio management for Foxconn’s efforts in healthcare and the life sciences. Key interests include digital health, connected devices, genomics, and molecular diagnostics. Previously, Ben was a Vice President at WI Harper Group – an early-stage venture capital firm, working out of the San Francisco and Taipei offices, where he sourced and managed investments in both healthcare and technology sectors. Ben was born and raised in Silicon Valley. He holds a Bachelor of Science from Cornell University in Genetics and Bioengineering and curious about almost anything.

- **Bill Kohlbrenner**, CEO, NeuroLucent
  Dr. Kohlbrenner is currently Chief Scientific Officer at Life Science Nation (LSN) and is Consulting Scientist for Boston Innovation Capital. In addition, he is CEO of NeuroLucent, a Chicago-based company working on Alzheimer’s disease. Prior to joining LSN, Bill was a director at AbbVie, where he led a global scouting team and conducted strategic assessments of early- and late-stage pipeline opportunities. Earlier in his career, Bill led drug discovery research programs in oncology, antivirals and antibacterials. Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.

- **Brian Po-Hui Chen**, Executive Director, Daiwa Corporate Investment
  Dr. Chen joined Daiwa Corporate Investment (DCI) group in 2015, together with DCI/DCI partners (DCIP) teams to establish and manage the TW-JP bio fund, including raising the fund, investment, and post-investment value-adding management, with active participation in the biomedical industry. Before joining DCI, Dr. Chen used to work for Nankang Biotech Incubation Center (NBIC), Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), Development Center for Biotechnology (DCB). Acting as a BD director completing important projects such as CTPS department transaction and BPPF spin-off, Dr. Chen is familiar with corporate development, investment, event organization, industry promotion. Not only in biotech industry, Dr. Chen is also experienced in equity investment and acting as important roles in diversified professional societies and industries such as CFA Society Taiwan and MJ Taiwan, with extensive network and capability of cross-border integration.

- **Byron Kalogerou**, Partner, McDermott Will & Emery, Boston
  Byron S. Kalogerou is the Chair of the Firm’s Life Science Industry Group and head of the Boston Corporate Advisory Practice Group. Byron focuses his practice on domestic and cross border mergers and acquisitions, corporate finance and joint ventures and alliances. He has substantial on the ground experience in structuring mergers, acquisitions, divestitures and joint ventures on six continents. Byron has extensive industry background in the medical device, fire and security, energy, telecom and industrial sectors. Before his move back to private practice, Byron spent 17 years in-house, including 14 years at Tyco International, where he served in a variety of roles including as general counsel of its fire and security business, its telecommunications business and as general counsel of its international legal department, a function he created. He has handled hundreds of M&A transactions. These include Tyco’s most significant transactions, including the $12 billion acquisition of AMP Inc., the $850 million purchase of AT&T Submarine Systems, and the $2.2 billion initial public offering of TyCom Ltd. In addition, he handled many of Tyco’s medical device company acquisitions.
Cindy Lin, Senior Associate, Perseverance Capital
Cindy is a Senior Investment Associate at Perseverance Capital Management, a US based healthcare focused fund, and is currently the representative for its Taipei office. Cindy joined Perseverance in 2017 and spent one year in Seattle working for the fund before relocating to Taipei. She evaluates primary and secondary fund investments as well as co-investment opportunities. Cindy was also a summer associate at Dreamit Ventures, a NYC based accelerator, where she evaluated startups that seek to join the accelerating program. Cindy has a BA in Economics and Political Science from University of Illinois at Urbana Champaign and received her MBA from Columbia Business School.

Dale Van Demark, Partner, McDermott Will & Emery, Washington DC
Dale C. Van Demark advises clients in the health industry on strategic transactions and the evolution of health care delivery models. He has extensive experience in health system affiliations and joint venture transactions. Dale also provides counsel on the development of technology in health care delivery, with a particular emphasis on telemedicine. Dale has been at the forefront of advising clients with respect to the globalization of the US health care industry. He advises US and non-US enterprises with respect to the formation of cross-border affiliations and international patient programs. In addition to writing regularly on matters related to his practice, Dale has spoken at numerous conferences around the world on the globalization of health care. He is also a member of our legal cannabis industry group. Our Cannabis Industry group is a multidisciplinary team of lawyers providing clients with regulatory, litigation, intellectual property, trade and tax services with respect to their investments and participation in the cannabis industry, all subject to the Firm’s obligations under federal and state laws and bar licensure rules.

David Uffer, Senior Partner, VP of MedTech, Alira Health
David Uffer joined Alira Health with over 25 years of management experience in the medical device, products and clinical diagnostics field. He has lead strategy development, strategic planning and business development activities in these fields for mid and large cap public companies. David has directed business development deals ranging from M&A, licensing, distribution and co-development for companies such as Medtronic (legacy Covidien) in their respiratory and medical products business, as well as Hologic and Boston Scientific. He has held management roles at Integra Lifesciences and Abbott Labs. David has a BA from Clark University, Worcester, MA and an MBA from Thunderbird, School of Global Management, Glendale, AZ.

David Ong, Investment Manager, Lucima Gruppo
LUCIMA GRUPPO is an international investment firm based in Taipei, Taiwan. Our current healthcare and medical device portfolio includes Suntop Healthcare Corporation, a provider of hemodialysis service in China, and AcuSolutions, a developer of optical sectioning device being tested in UCSF. Prior to joining LUCIMA GRUPPO, David worked at SinoPac Venture Capital (Taipei) and Tripod Capital (Beijing). Before venturing into investments, David was an interventional cardiologist in Peking University First Hospital and was responsible for pre-clinical/clinical study of innovative coronary stent. David holds a MD from Peking University and a MBA from Vlerick Business School.

Dennis Lee, Venture Partner, Industrial Technology Investment Corporation
Return to Taiwan from the Bay Area. And started Studio88 Design Corp, a MedTech Design Consulting Firm in 2013. Specialize in Innovative Medical Device’s Product-Market Fit of Asia Pacific, Europe, and North America. Believer of Lean Startup launchpad, practice Evidence-Based Design and work closely with International Medical Device Manufacturers and International Medtech Startups to develop their innovative solutions. Step into the early-stage investments focus on evaluating combination of Clinical and Business Unmet Needs in Healthcare Ecosystem.

Diana Cheng, Senior Director, Biofund Investment, Taiwania Capital
Diana Cheng, possesses passion and hands-on experience in various pharmaceutical topics, including new drug development, clinical trials management, life cycle strategies, particular in MSL development/management and local/regional medical affairs activities within Asia-Pacific. Her previous therapeutic area of expertise ranged across oncology, neurology, ophthalmology, cardiovascular diseases, infectious diseases, HIV, and Vaccines. Serving as Senior Investment Director in Taiwania Capital—a venture capital firm backed by Taiwan Development Council, Diana is responsible for due diligence activities and provides critical support to the portfolio companies. She committed to contribute and build the developing biotech ecosystem in Taiwan. In the longer term, Diana envisions herself to lead and be involved in more critical resource allocation decisions in the Global R&D, commercialization, business development, licensing, and alliance management, where she thinks the greatest impact to be made to improve human healthcare. Diana holds an MBA in Finance and Healthcare Management from Columbia Business School in the New York City and a MD from National Taiwan University.
• **Emmanuelle Trombe**, Partner, McDermott Will & Emery, Paris

Emmanuelle Trombe represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. Emmanuelle Trombe is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is recommended for her expertise in the pharmaceutical, health care, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded.

• **Henderson Hsieh**, Research Section Manager, Quanta Computer Inc.

Yao-Fang Hsieh is responsible for market research and investment at Quanta Computer. Previously, he worked as an industry analyst at the Digitimes, Fuh Hua Investment Trust, and Institute for Information Industry. His main areas of market research interest concern digital health, medical device, precision medicine, and AI medicine. Yao Fang received his Ph.D. in Optics and Photonics from National Central University.

• **Hsuan-Pu Chen**, Investment Manager, Taiwania Capital

Dr. Hsuan Pu Chen graduated from UCLA biomedical engineering department. Prior to joining Taiwania Capital, he was a deputy director and project leader in Fountain Biopharma Inc., project leader in DCB, Taiwan, manager in Kimforest Biotech, and post-doc (research fellow) in UCSF. With more than 8 years of industrial experience, Dr. Chen specializes in biomedical data mining, molecular biology, and drug development.

• **Jack Liu**, Director, R&D & Incubation, BE Capital

Dr. Kai-Che Jack Liu is the Chairman and CEO of MedicalTek Co., Ltd (MDTK). MDTK is devoted to advance medical imaging of minimally invasive surgery (MIS). Dr. Liu is also the Director of the R&D in IRCAD-Taiwan. IRCAD-Taiwan is the education and innovation center of minimally invasive surgery. Prior to these two current positions, he served as the assistant manager in Electronic and Opto-Electronics Research Laboratories (EOL) of Industrial Technology Research Institute (ITRI), and played a key research role in the development of Taiwan’s 3D high-tech industries. Currently Dr. Liu also works together with BE Capital to build the minimally invasive surgery accelerator in Taiwan.

• **James Huang**, Managing Partner, KPCB China/ Panacea Venture

James Huang joined Kleiner Perkins Caufield & Byers China as a managing partner in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Before coming to KPCB China, James was a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. Before joining Vivo in 2007, James was president of Aesiva, a biopharmaceutical company focused on pain-management treatments. Meanwhile, James Huang is also founding and Managing Partner to Panacea Venture. Panacea Venture is focusing on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide, is established and managed by experienced partners Mr. James Huang whom is KPCB China’s managing partner. James received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

• **Jane Tsai**, Senior Vice President for International Affairs, YFY Biotech Management Company

Jane Tsai is Senior Vice President of International Affairs at YFY Biotech Management Company. She is an experienced executive leader in transforming inventions and innovation into business value, Jane has enjoyed professional success in directing hundreds of researchers and specialists in the fields of healthcare, medical devices, biotechnology and drug development. She has engaged global collaborators and facilitated diverse partnerships. A leader of award-winning cross-sector projects, Jane has empowered interdisciplinary teams to drive product development, commercialization, lifecycle management, and to deliver portfolios with higher strategic value and superior business outcome.

• **John Lin**, Investment Director, Abico Asia Capital

John Lin is an investment director with Abico Asia Capital, based in Taipei. John is experienced in identifying investment and buyout ideas within the healthcare and electric vehicle sectors, and managing investments on an end-to-end basis. He is committed to increase enterprise value with local networks and regional resource and has closed deals across Japan, China, ASEAN and Taiwan. Prior to joining Abico Asia Capital in 2017, he spent 3 years in CDIB capital group. He is also active in startup community, as Venture Consultant of Taipei City Government of Taiwan, he advises founders and executives on top-management level topics including fundraising, corporate strategy, mergers and acquisitions. John holds a MBA from National Chengchi University.
• Rae Lin, Investment Analyst, GRC SinoGreen Fund

Mr. Rae Lin joined GRC SinoGreen Fund in 2017. As an investment analyst, he is responsible for deal sourcing and screening, providing in-depth industry research, supporting the due diligence process and the post-investment management. In the past two years, Mr. Lin followed and observed the current development and future trends of several industries, including AI medical imaging, AI drug discovery, advanced medical equipment, etc. Before Mr. Lin joined GRC, he worked as an analyst at Taiwan branch of Daiwa Capital Market, the second largest broker in Japan, supporting the Asia small- and mid-cap sector team. Previously, he was a research associate in a global tech hedge fund.

• Robert Liu, Managing Director, CDIB Capital Management

Robert is Managing Director of healthcare investment sat CDIB Capital Group. Prior to joining CDIB, he was Principal, Venture Investments at Johnson & Johnson Development Corporation (JJDC), responsible for the venture and private equity investments in life science and healthcare in Asia Pacific region. Prior to JJDC, Robert served as Director of Business Development & Strategy of Greater China at GlaxoSmithKline, and worked in the Global Corporate Development & Strategy team of Charles River Laboratories, in Boston USA. Robert has executed over $3 billion M&A and investment transactions in the US, Europe and Asia. Robert holds a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago Booth School of Business and a Master Degree in Medicine (7-year program) from Tongji Medical University. Robert also received the residency training in Urology at Union Hospital, Wuhan China.

• Sarah Columbia, Partner, McDermott Will & Emery, Boston

Sarah Chapin Columbia is a Fellow in the American College of Trial Lawyers. Over the last nine years, she has led 14 patent infringement and validity trials (eight jury trials, six bench trials) across several jurisdictions, including the federal courts in Massachusetts, Florida, Delaware, California and Texas. Sarah also counsels clients on overall intellectual property strategy and positioning, including litigation avoidance. She provides legal services across several industries, including semiconductor, pharma/biotech, internet, hardware and software, medical device and manufacturing companies. Sarah is a member of the faculty of the Munich Intellectual Property Law Center, where each year she teaches a two-day course focused on US patent litigation.

• Susie Hong, Assistant Vice President, Saga Unitek Ventures

Susie Hong is an Assistant Vice President. Prior joined Saga Unitek, she served as an Assistant Vice President at Capital Management Co., Ltd.; a Senior Investment Manager at Honho Management Co. She holds an MBA from W. Texas A&M University, a MS from University of Washington and a BA from Fu-Jen Catholic University.

• TC Chou, President, Harbinger Venture Management

Dr. Chou co-founded Harbinger Venture in 2000 and has built Harbinger to be a Pan-Pacific early to mid-stage value-added technology venture firm with over 150 portfolio companies in Greater China and Silicon Valley. Before founding Harbinger, he also served as General Manager of Tianjin Datian Enterprise Co. Ltd.; Vice President of Ek Chor Distribution Co. Ltd. in China; and Director of Corporate Development at Roll International in California. Dr. Chou specializes in mergers and acquisitions, venture investment, and incubation. He has brought over 60 companies to public and been instrumental in several successful M&A deals of his portfolio companies. Dr. Chou holds a Ph.D. from Rutgers, and an MBA from Wharton.

• Wayne Huang, Partner, BE Capital

Dr. Huang graduated from Tulane school of medicine and Tulane school of public health in New Orleans, USA, in year 2005. After that, he returned to Taiwan to start his surgical residency training. After finishing residency training in Showchwan Memorial hospital, he spent 5 months in Ircad France to train in Upper Gastrointestinal Surgery under professor Marescaux and Professor Dallemagne. He has actively participated in all activities in Ircad Taiwan, and has gained reputation as a trainer in MIS. He has also been involved in developing surgical training workshop in Ircad Taiwan. He is invited internationally for his expertise in surgical education, laparoscopic surgeries techniques, and medical device entrepreneurship. He started the role as director of Ircad Taiwan since 2018. He is currently undergoing PhD in Tokyo Women's Medical University under Professor Yamamoto.

• Yuwen Liu, Founding Partner, BOHE Angel Fund

Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Appotec, Hengrui, Simcere, TigerMed and BGI, etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China. Before BOHE, she was Chairwoman & CEO then executive director of BioBAY for 9 years. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies. She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation. She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.
RESI provides a partnering forum for all stakeholders in the early stage life science world to reach out to others and build the relationships that will carry new technologies towards commercialization.
FUELING
YOUR
MISSION.

We provide comprehensive legal counsel to support healthcare and life sciences investments and operations.

A leading international law firm, McDermott propels the success of the world’s most respected, dynamic and important life sciences organizations. We help clients enter, expand and thrive in the most complex markets around the world. Through our strategic alliance with MWE China Law Offices in Shanghai, we deliver industry-leading services to life sciences leaders looking to clear their path to success.

VISIT US AT MWE.COM/LIFESCIENCES
**Life Science Nation** accelerates fundraising with its matching platform to create relationships between early stage scientist entrepreneurs and emerging life science investors.

**INVESTOR PLATFORM**

5,000 early stage life science investors across 10 categories

**COMPANY PLATFORM**

55,000 emerging biotech, medtech, diagnostic and healthcare IT companies

**FOCUS ON CURES ACCELERATOR**

- MKT 466 Funding and Partnering Immersion Course
- Branding & Messaging
- Fundraising Workshops
- Sourcing & Ranking Service

---

**FUNDRAISING ADVISORY FIRM**

Providing tactical assistance in executing fundraising campaigns in the biotech and medtech arenas

**GLOBAL NETWORK OF INVESTORS**

Securing meetings and fostering relationships with qualified investors that are a fit

**INTEGRATED WITH LSN & RESI**

Making your fundraising more efficient and effective based on technology and relationships

---

LifeScienceNation.com | RESIconference.com | BostonInnovationCapital.com